Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100801 | 0.87 | TRPV4 (0.39) | SLC6A2SLC6A4SLC6A3KDM4EMAPT | |
| SCHEMBL16676222 | 0.80 | KDM4E (0.57) | SLC6A2SLC6A4SLC6A3KDM4EMAPT | |
| SCHEMBL694015 | 0.78 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KDM4EMAPT | |
| SCHEMBL694090 | 0.76 | TRPV4 (0.44) | KDM4EMAPTHPGDMEN1KMT2A | |
| SCHEMBL6516138 | 0.75 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KDM4EMAPT | |
| SCHEMBL695747 | 0.75 | VCAM1 (0.57) | L3MBTL1PDE7A | |
| SCHEMBL2638690 | 0.73 | ADORA2A (0.40) | SLC6A2SLC6A4SLC6A3KDM4EMAPT | |
| SCHEMBL3103805 | 0.73 | VCAM1 (0.51) | L3MBTL1PDE7A | |
| SCHEMBL30873036 | 0.69 | TSHR (0.50) | SLC6A2SLC6A4SLC6A3KDM4ECYP3A4 | |
| SCHEMBL1026066 | 0.69 | TSHR (0.50) | SLC6A2SLC6A4SLC6A3KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2749554-B1 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | SMA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2749554-B1 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | SMA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| CN-102459177-B | The dibasic Arylsulfonamide ccr 3 antagonists of 2,5- | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-09-02 | — | — | CN | disclosed |
| EP-2749554-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2749554-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20140066446-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8563544-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2421830-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123959-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123959-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | SLC6A2 2308/4885SLC6A4 1650/4885SLC6A3 427/4885 |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | SLC6A2 2439/4885SLC6A4 1745/4885SLC6A3 634/4885 |
| US-20140066446-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | SLC6A2 2308/4885SLC6A4 1650/4885SLC6A3 427/4885 |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | SLC6A2 2308/4885SLC6A4 1650/4885SLC6A3 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.